Klaus Christensen, CCO

M.Sc. i Business Administration & Economics from Copenhagen Business School (Danmark), with more than 25 years of experience in global roles in commercialization, business development and pricing. Klaus has exercised commercial leadership ranging from early development to product launches for several pharmaceutical companies, including AstraZeneca and LEO Pharma.

Shareholdings: 40 000 shares and 20 000 warrants TO5 and 20 000 TO6